Design: retrospective case review. Methods: We performed a retrospective review of sMH with a size of at least 1 disc diameter. sMH causes were classified into 3 groups: 1) neovascular age-related macular degeneration (naMd), 2) polypoidal choroidal vasculopathy (PcV), and 3) other miscellaneous causes.
S ubmacular hemorrhage (sMH) is defined as the presence of blood in the space between the retinal pigment epithelium (rPE) and the neurosensory retina at the macular area arising from choroidal and retinal vessel abnormalities. submacular hemorrhage may complicate numerous ocular diseases, including neovascular age-related macular degeneration (naMd), polypoidal choroidal vasculopathy (PcV), retinal arterial macroaneurysm, pathologic myopia, tumors, choroidal neovascularization of various etiology, and trauma.
1-11 the natural history and visual outcomes of sMH resulting from aMd are typically poor, whereas sMH from other causes have been reported to be associated with better visual prognosis.
12 degeneration of the outer retina resulting from blood accumulation between photoreceptors and rPE, such as iron toxicity from erythrocyte degeneration, fibrin contraction, and fibrocellular scar formation, explain unfavorable visual prognosis 13, 14 even after hemorrhage has resolved. though there are several treatment options available, the treatment of sMH remains challenging.
in this report, we describe the causes, visual outcomes, and associated prognostic factors in 98 consecutive patients with sMH from thailand. materials and methods a retrospective review was performed of consecutive patients diagnosed with sMH between January 2008 and december 2013 at the department of ophthalmology of chiang Mai university Hospital, thailand. submacular hemorrhage was defined as an accumulation of blood between the neurosensory retina and rPE or under the rPE with a size of at least 1 disc diameter (dd), which in all cases extended under the fovea. Patients with combined naMd with PcV (n = 3), ambiguous patients who presented difficulty in differentiating naMd from PcV (n = 5), and other ocular morbidities potentially affecting the results of the examinations and visual function (n = 2; 1 with dense cataract, 1 with corneal scar) were excluded from the study. in bilateral cases (n = 2), only the eye with worse visual acuity at presentation was included in the study. demographic data, including age, sex, laterality, underlying diseases, disease duration, diagnosis, and follow-up duration, were registered. all patients were evaluated with visual acuity testing (best-corrected snellen visual acuity; BcVa), dilated fundus examination with slit-lamp biomicroscopy and 78-diopter (d) magnifying lens, color fundus photography, and spectral domain optical coherence tomography (sd-oct). all patients also underwent fundus fluorescein angiography (Fa) and indocyanine green angiography (icga) when sMH had adequately resolved to perform the test. submacular hemorrhage patients were classified into 3 groups, specifically, 1) neovascular age-related macular degeneration (naMd-associated sMH), 2) polypoidal choroidal vasculopathy (PcV-associated sMH), and 3) miscellaneous group. the diagnosis of PcV was based on EVErEst study report 2 criteria.
15 in short, these included an early subretinal hyperfluorescence on icga and at least 1 of the following diagnostic criteria: nodular appearance of the polyp(s) on icga, hypofluorescent halo around the nodule(s), abnormal vascular channel(s) supplying the polyps, pulsatile filling of polyps and orange subretinal nodules on fundus photography corresponding to the polyp(s) on ICGA. Neovascular AMD-associated SMH was diagnosed in cases showing exudative aMd signs without any PcV features *included 2 cases with neovascularization secondary to uveitis, 2 with myopic cnV, 2 with retinal arterial macroaneurysms, 2 due to branch retinal vein occlusion, and 2 idiopathic cases. †there were in total 5 patients with a follow-up less than 1 month (3 PcV, 2 aMd). ‡one-way anoVa test. §Pearson χ 2 test. ¶Kruskal-Wallis test.
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© 2017 Asia-Pacific Academy of Ophthalmology on icga. all sMH from other causes except naMd or PcV were classified into the miscellaneous group. Visual acuity was tested using snellen acuity chart and converted to Early treatment diabetic retinopathy study (Etdrs) letter scores for all calculations and statistical analyses. a difference of −0.3 logarithm of the minimum angle of resolution (logMar) or less and +0.3 logMar or more from the initial Va was classified as a significant change of Va, respectively (each 0.3 logMar difference = doubling of the visual angle). statistical analyses were performed using student t test, Mann-Whitney U test, Kruskal-Wallis test; analysis of variance (anoVa) tests were used for continuous variables and Fisher exact test or Pearson χ 2 test were used for categorical variables with the software package SPSS 17.0 (SPSS Inc, Chicago, IL). A significance level of 5% was used.
the study was approved by the Ethics committee of chiang Mai university Hospital and conformed to the declaration of Helsinki. results this study included 98 eyes of 98 patients. Based on clinical presentation and all ancillary examinations, patients were classified into 3 groups: diagnosis of PcV (n = 58; 59%), naMd (n = 30; 31%), and other miscellaneous causes of sMH (n = 10; 10%) (table 1). associated systemic diseases included systemic hypertension (30/98; 31%), diabetes mellitus (16/98; 16%), and dyslipidemia (9/98; 9%) and their prevalence did not differ between the 3 sMH groups. the presenting characteristics of the patients, such as age (P = 0.070), hemorrhagic area (P = 0.153), sex (P = 0.734), initial Va (P = 0.061), and the specific cause of sMH (P = 0.58), did not differ between the patients with a followup shorter and longer than 6 months.
comparison between the PcV and naMd groups is shown in table 2. Patients with PcV-associated sMH commonly had a hemorrhagic size of at least 4 dd [P = 0.03; odds ratio (or), 3.157; 1. 209-8.244 ]. The patients with nAMD-associated SMH were older than in other groups (P = 0.009; OR, 4.044; 1.5-10.902) and there was a slight predominance of males (P = 0.018). Further, patients with naMd-associated sMH had poor initial Va and Va at follow-up of 6 months (P = 0.05; OR, 2.628; 1.058-6.530 and P = 0.029; OR, 6.923; respectively) .
overtime, all groups improved in Va (table 1) . though a majority of naMd-associated sMH improved, the visual outcome in this group remained limited (median Va of 0.8 logMar). at 6-month follow-up, 67% (12/18) of naMd patients improved and 33% (6/18) remained stable, whereas Va in PcV patients improved in 58% (22/38), worsened in 13% (5/38), and remained stable in 30% (11/38).
the treatment modalities used in this retrospective series varied widely and included observation only; monotherapy with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) injections, focal laser photocoagulation, or photodynamic therapy (Pdt); further combinations of iVt anti-VEgF injections with Pdt or pneumatic displacement or pars plana vitrectomy (PPV) along with PPV and recombinant tissue plasminogen activator. Most patients had been treated with anti-VEgF (81%; n = 79), followed by pneumatic displacement (35%; n = 34), Pdt (27%; n = 26), PPV (15%; n = 15), and laser photocoagulation (4%; n = 4). Photodynamic therapy was more commonly employed in PcV compared with naMd (P = 0.004).
Poor visual outcome (greater than 1.0 logMar) at 6 months (n = 61, table 3) was associated with poor initial Va greater than 1.0 logMar (P = 0.002; OR, 1.369; 1.084-1.728) and the diagnosis of naMd-associated sMH (P = 0.02; OR, 7.885; 1.364-45.577). age older than 65 years exhibited borderline association with very poor outcome (P = 0.052).
Multivariate analysis revealed that visual outcome of more than 1.3 logMar was associated with sMH duration of more than 2 months (P = 0.012; OR, 36.955: 2.179-626.769). The recurrence rate in PcV-associated sMH and naMd-associated sMH did not differ (7% in PcV and 10% in naMd within 6 months; P = 0.686).
discussion our study from thailand shows that in our geographical area, PcV was a predominant cause of sMH. We further demonstrated that visual outcomes were limited for patients with naMdassociated sMH, for those with poor initial Va, and for patients older than 65 years. Further, the persistence of sMH for at least 2 months was associated with poor visual outcome.
in this study, the most common cause of sMH was PcV, which is consistent with other studies from asia and differs from studies from the West where naMd was reported to be the most common cause of sMH. 5, 6, [16] [17] [18] [19] [20] the predominance of PcV in our sMH series might be explained by several factors. First, PcV is more prevalent in Asian populations (varies from 10-59% in asian patients with presumed naMd [20] [21] [22] [23] [24] and is commonly associated with SMH, with an incidence of 30-56% 15, 24, 25 ). secondly, our study included only patients with sMH of at least 1 dd. it might be possible that sMH of more than 1 dd are more common in PcV. lastly, we performed icga in all cases. this is an important tool for detecting PcV lesions, especially in patients with sMH, because it allows visualization of the choroid despite the presence of hemorrhage.
26-31 our study highlights the importance of icga in the correct diagnosis of the cause of sMH, as the correct diagnosis of PcV based on clinical signs and oct could be performed only in 50% of PcV cases (table 1) . new techniques such as swept-source oct may become more useful diagnostic tools in the future as they combine higher sensitivity with higher imaging depth and longer imaging range.
the visual prognosis of untreated sMH is usually poor, 3, 4, 32, 33 especially in patients with massive sMH extending beyond the temporal arcades. 1-3,14,34 the aim of treatment is to clear sMH and treat the underlying cause of the bleeding before the structural changes in adjacent tissues occur. the choice of specific treatment modality obviously depends on the specific cause of bleeding. up to 80% of our patients received anti-VEgF injections, either as monotherapy (in 25%) or in combination with other treatment modalities therapy (55%). our study was not designed to compare the efficacy of treatment approaches and we could not link a single therapeutic modality to visual prognosis, which is undoubtedly due to various treatment regimens in our retrospective study.
so far, the published reports on visual outcomes of specific sMH types are not consistent. in our series, naMd-associated sMH exhibited a poor visual outcome in long-term follow-up. although PcV-associated sMH showed a similar clinical pattern, the short-term visual outcomes were better. our results are in agreement with earlier studies where visual prognosis for PcVassociated sMH was generally reported to be superior to naMdassociated sMH because of less subretinal fibrovascular proliferation and less rapid formation of disciform scarring. 16, 20, 24, [35] [36] [37] in contrast, other studies [38] [39] [40] reported that PcV represents a more chronic disorder with a high chance of recurrent hemorrhage and was associated with higher incidence of long-term visual loss compared with naMd-associated sMH. occasionally, PcV can cause massive sMH, which may result in severe rPE atrophy and permanent visual loss.
32,41-43 in our study, 42 patients with 
Characteristic
© 2017 Asia-Pacific Academy of Ophthalmology massive sMH were included, 74% with PcV. it is feasible that with a longer duration of follow-up, the visual prognosis of PcV might gradually become worse. cho et al 44 have shown that PcV patients had a substantial risk of massive sMH and experienced more severe vision loss at 10-year follow-up after the initial visit. the incidence rate of massive sMH in PcV increased with follow-up time regardless of the treatment given. the favorable visual outcome of the miscellaneous group in our series (even though 30% of patients remained without treatment) might be influenced by the better prognosis of the underlying retinal disorders.
Previous studies on sMH 20,45-48 reported variable prognostic factors, such as initial Va, cause and size of sMH, age, and hypertension. in our retrospective study, poor initial Va (more than 1.0 logMar) and diagnosis of naMd as the underlying cause of sMH formed significant predictors for poor visual prognosis in our geographical area. these findings are consistent with several previous studies from asia. 45, 48 We also identified that long duration of sMH (more than 2 months) was associated with a very poor visual outcome, which was previously not noted by others.
the limitations of our study include its retrospective design and limited number of patients included, along with limited follow-up. However, follow-up examinations in our region are not always attended. Patients with sMH exhibit large variations in terms of age, causes, clinical manifestations, and visual acuity at the first presentation to an ophthalmologist. our data do not allow a comparison of efficacy of diverse treatment modalities.
in conclusion, despite the limitations of our study, our series from southeast asia clearly shows that in our region PcV was the most common cause of sMH. indocyanine green angiography represented a valuable tool for the diagnosis of the exact cause of sMH. though Va slightly improved in all groups over time, the long-term visual outcomes were limited for patients with naMdassociated sMH, for those with poor initial Va, and for patients older than 65 years. Persistent sMH for more than 2 months was also associated with poor visual outcome. 
